Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 2B

CHEMBL1833 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1833
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 2B as ChEMBL target CHEMBL1833, mapped to UniProt P41595. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 2B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1833
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P41595
5-hydroxytryptamine receptor 2B
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 2B matters

As of 2026-09-14

5-hydroxytryptamine receptor 2B is reviewed as 5-hydroxytryptamine receptor 2B (UniProt P41595); 5-hydroxytryptamine receptor 2B shows approved-linked disease relevance led by hemorrhage.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 197 approved drugs, 5517 compounds, and 951 assays, with lead potency reaching pChEMBL 10.2.

Disease context
hemorrhage

5-hydroxytryptamine receptor 2B shows approved-linked disease relevance led by hemorrhage. 1 linked drug keep the rationale reviewable. Linked drugs include METHYLERGONOVINE MALEATE.

Start review with hemorrhage because it currently carries approved-linked support. Linked drugs include METHYLERGONOVINE MALEATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 197 approved drugs, 5517 compounds, and 951 assays for this target. The dominant activity type is KI. CHEMBL39 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL39 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
197 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 2B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P41595, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hemorrhage is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5517
Total Compounds
951
Total Assays
197
Approved Drugs
IC50: 1159.0, KI: 2916.0, EC50: 997.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL39
 10.2 EC50 Clinical
No preferred name
CHEMBL3310115
 10.0 Ki —
No preferred name
CHEMBL2028019
 9.8 Ki Approved
No preferred name
CHEMBL149024
 9.7 Ki —
No preferred name
CHEMBL5095172
 9.7 Ki Clinical

Approved Drugs

Structure Compound First Approval
XANOMELINE
CHEMBL21536
 2024
CARIPRAZINE
CHEMBL2028019
 2015
BREXPIPRAZOLE
CHEMBL2105760
 2015
LORCASERIN
CHEMBL360328
 2012
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
ASENAPINE
CHEMBL3187365
 2009
SORAFENIB
CHEMBL1336
 2005
CINACALCET HYDROCHLORIDE
CHEMBL1200776
 2004
ARIPIPRAZOLE
CHEMBL1112
 2002
TEGASEROD MALEATE
CHEMBL1516474
 2002
ZIPRASIDONE
CHEMBL708
 2001
APOMORPHINE
CHEMBL53
 2001
DESLORATADINE
CHEMBL1172
 2001
ALOSETRON
CHEMBL1110
 2000
KETOTIFEN
CHEMBL534
 1999
TROGLITAZONE
CHEMBL408
 1997
QUETIAPINE
CHEMBL716
 1997
RALOXIFENE
CHEMBL81
 1997
CABERGOLINE
CHEMBL1201087
 1996
AZELASTINE
CHEMBL639
 1996
OLANZAPINE
CHEMBL715
 1996
CARVEDILOL
CHEMBL723
 1995
RISPERIDONE
CHEMBL85
 1993
CISAPRIDE
CHEMBL1729
 1993
LORATADINE
CHEMBL998
 1993
ONDANSETRON
CHEMBL46
 1991
DOXAZOSIN
CHEMBL707
 1990
EBASTINE
CHEMBL305660
 1990
DAPIPRAZOLE
CHEMBL1201216
 1990
PROPAFENONE
CHEMBL631
 1989
CLOMIPRAMINE
CHEMBL415
 1989
CLOZAPINE
CHEMBL42
 1989
ASTEMIZOLE
CHEMBL296419
 1988
PERGOLIDE
CHEMBL531
 1988
BUSPIRONE
CHEMBL49
 1986
AMISULPRIDE
CHEMBL243712
 1986
TERFENADINE
CHEMBL17157
 1985
MEXILETINE
CHEMBL558
 1985
AMIODARONE
CHEMBL633
 1985
CYCLIZINE
CHEMBL648
 1982
GUANABENZ
CHEMBL420
 1982
ISOTRETINOIN
CHEMBL547
 1982
TRAZODONE
CHEMBL621
 1981
VERAPAMIL
CHEMBL6966
 1981
AMOXAPINE
CHEMBL1113
 1980
MAPROTILINE
CHEMBL21731
 1980
METOCLOPRAMIDE
CHEMBL86
 1979
SULOCTIDIL
CHEMBL404849
 1979
BROMOCRIPTINE
CHEMBL493
 1978
CLEMASTINE
CHEMBL1626
 1977
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1833